Home/Filings/4/0000899243-20-005516
4//SEC Filing

Smith Bryan E. 4

Accession 0000899243-20-005516

CIK 0001740547other

Filed

Feb 20, 7:00 PM ET

Accepted

Feb 21, 6:42 PM ET

Size

10.5 KB

Accession

0000899243-20-005516

Insider Transaction Report

Form 4
Period: 2020-02-19
Smith Bryan E.
GC of Urovant Sciences,Inc.
Transactions
  • Exercise/Conversion

    Common Shares

    2020-02-19$6.88/sh+50,000$344,000100,000 total
  • Tax Payment

    Common Shares

    2020-02-19$13.08/sh34,835$455,64265,165 total
  • Other

    Common Shares

    2020-02-19$13.08/sh15,165$198,35850,000 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2020-02-19+50,00020,000 total
    Exercise: $6.88Exp: 2029-01-06Common Shares (50,000 underlying)
Footnotes (3)
  • [F1]Represents 26,300 shares surrendered to the Issuer in satisfaction of payment of exercise price and 8,535 shares surrendered to the Issuer in satisfaction of the payment of required withholding taxes in connection with the exercise of stock options.
  • [F2]Represents the sale of 15,165 shares of common stock to Sumitovant Biopharma Ltd., a subsidiary of Dainippon Sumitomo Pharma, in a privately-negotiated transaction.
  • [F3]All of the shares underlying this option are vested and exercisable as of the date hereof.

Issuer

Urovant Sciences Ltd.

CIK 0001740547

Entity typeother

Related Parties

1
  • filerCIK 0001748041

Filing Metadata

Form type
4
Filed
Feb 20, 7:00 PM ET
Accepted
Feb 21, 6:42 PM ET
Size
10.5 KB